A polymer-protein core-shell nanomedicine for inhibiting cancer migration followed by photo-triggered killing

Journal of Biomedical Nanotechnology

Volumn 10, Issue 8, 2014, Pages 1401-1415

  Ramachandran, Ranjith ^a   Malarvizhi, Giridharan Loghanathan ^a   Chandran, Parwathy ^a   Gupta, Neha ^a   Menon, Deepthy ^a   Panikar, Dilip ^a   Nair, Shantikumar ^a   Koyakutty, Manzoor ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Core Shell nanomedicine; Dasatinib, Src inhibition; Glioma. mTHPP; Photodynamic therapy

Indexed keywords

CELL DEATH; COPOLYMERS; DISEASES; ENZYMES; MEDICAL NANOTECHNOLOGY; OXYGEN; PATHOLOGY; PHOTODYNAMIC THERAPY; PHOTOSENSITIZERS; POLYMERS; PROTEINS; TRANSMISSION ELECTRON MICROSCOPY; TUMORS;

CORE-SHELL; DASATINIB; ELECTROSPRAY TECHNIQUES; GLIOMA. MTHPP; INTRAVENOUS ADMINISTRATION; PHOTOPHYSICAL PROPERTIES; PHYSIOLOGICAL CONDITION; POLY(LACTIC-CO-GLYCOLIC ACID);

SHELLS (STRUCTURES);

ALBUMIN; ALCOHOL; DASATINIB; NANOSHELL; PHOTOSENSITIZING AGENT; POLYGLACTIN; POLYMER; PORPHYRIN DERIVATIVE; REACTIVE OXYGEN METABOLITE; SINGLET OXYGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOCOMPATIBILITY; CANCER CELL; CANCER CELL CULTURE; CELL DEATH; CELL MIGRATION; CELL MIGRATION ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ELECTROSPRAY; FLUORESCENCE ACTIVATED CELL SORTING; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; LASER; MALE; NANOMEDICINE; NONHUMAN; PARTICLE SIZE; PHOTOSENSITIZATION; RAT; SCANNING ELECTRON MICROSCOPY; SIGNAL TRANSDUCTION; STRESS; TOXICITY; TRANSMISSION ELECTRON MICROSCOPY;

ALBUMINS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DRUG CARRIERS; HUMANS; LACTIC ACID; MALE; NANOMEDICINE; PHOTOSENSITIZING AGENTS; PHOTOTHERAPY; POLYGLYCOLIC ACID; PORPHYRINS; PYRIMIDINES; RATS; RATS, WISTAR; THIAZOLES;

EID: 84899694250     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1847     Document Type: Article

References (49)

1. M. Yilmaz and G. Christofori, Mechanisms of motility in metastasizing cells. Mol. Cancer Res. 8, 629 (2010).
2. P. Friedl and K. Wolf, Tumour-cell invasion and migration: Diversity and escape mechanisms. Nat. Rev. Cancer 3, 362 (2003).
3. T. D. Palmer, W. J. Ashby, J. D. Lewis, and A. Zijlstra, Targeting tumor cell motility to prevent metastasis. Adv. Drug Deliv. Rev. 63, 568 (2011).
4. V. G. Brunton and M. C. Frame, Src and focal adhesion kinase as therapeutic targets in cancer. Curr. Opin. Pharmacol. 8, 427 (2008).
5. J. Araujo and C. Logothetis, Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat. Rev. 36, 492 (2010).
6. R. Buettner, T. Mesa, A. Vultur, F. Lee, and R. Jove, Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol. Cancer Res. 6, 1766 (2008).
7. J. Li, U. Rix, J. Gao, B. Fang, L. Song, Y. Bai, A. Edwards, S. Eschrich, J. Colinge, G. S. Furga, J. Koomen, and E. B. Haura, A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat. Chem. Biol. 6, 291 (2010).
8. C. V. Lund, M. T. Nguyen, G. C. Owens, A. J. Pakchoian, A. Shaterian, C. A. Kruse, and B. P. Eliceiri, Reduced glioma infiltration in Src-deficient mice. J. Neurooncol. 78, 19 (2006).
9. M. S. Ahluwalia, J. de Groot, W. M. Liu, and C. L. Gladson, Targeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studies. Cancer Lett. 298, 139 (2010).
10. M. P. Playford and M. D. Schaller, The interplay between Src and integrins in normal and tumor biology. Oncogene 23, 7928 (2004).
11. R. A. Klinghoffer, C. Sachsenmaier, J. A.Cooper, and P. Soriano, Src family kinases are required for integrin but not PDGFR signal transduction. EMBO J. 18, 2459 (1999).
12. J. S. Desgrosellier and D. A. Cheresh, Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10, 9 (2010).
13. J. Du, P. Bernasconi, K. R. Clauser, D. R. Mani, S. P. Finn, R. Beroukhim, M. Burns, B. Julian, X. P. Peng, H. Hieronymus, R. L. Maglathlin, T. A. Lewis, L. M. Liau, P. Nghiemphu, I. K. Mellinghoff, D. N. Louis, M. Loda, S. A. Carr, A. L. Kung, and T. R. Golub, Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat. Biotechnol. 27, 77 (2009).
14. J. N. Rich, Cancer stem cells in radiation resistance. Cancer Res. 67, 8980 (2007).
15. S. Bao, Q. Wu, R. E. McLendon, Y. Hao, Q. Shi, A. B. Hjelmeland, M. W. Dewhirst, D. D. Bigner, and J. N. Rich, Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756 (2006).
16. T. Zhao, X. Shen, L. Li, Z. Guan, N. Gao, P. Yuan, S. Q. Yao, Q. H. Xu, and G. Q. Xu, Gold nanorods as dual photo-sensitizing and imaging agents for two-photon photodynamic therapy. Nanoscale 4, 7712 (2012).
17. A. Babu, J. Periasamy, A. Gunasekaran, G. Kumaresan, S. Naicker, P. Gunasekaran, and R. Murugesan, Polyethylene glycol-modified gelatin/polylactic acid nanoparticles for enhanced photodynamic efficacy of a hypocrellin derivative in vitro. J. Biomed. Nanotechnol. 9, 177 (2013).
18. X. F. Qiao, J. C. Zhou, J. W. Xiao, Y. F. Wang, L. D. Sun, and C. H. Yan, Triple-functional core-shell structured upconversion luminescent nanoparticles covalently grafted with photosensitizer for luminescent, magnetic resonance imaging and photodynamic therapy in vitro. Nanoscale 4, 4611 (2012).
19. J. Sanchis, F. Canal, R. Lucas, and M. J. Vicent, Polymer-drug conjugates for novel molecular targets. Nanomedicine 5, 915 (2010).
20. A. O. Elzoghby, W. M. Samy, and N. A. Elgindy, Albumin-based nanoparticles as potential controlled release drug delivery systems. J. Control Release 157, 168 (2012).
21. G. Zhang, X. Zeng, and P. Li, Nanomaterials in cancer-therapy drug delivery system. J. Biomed. Nanotechnol. 9, 741 (2013).
22. A. P. Retnakumari, P. L. Hanumanthu, G. L. Malarvizhi, R. Prabhu, N. Sidharthan, M. V. Thampi, D. Menon, U. Mony, K. Menon, P. Keechilat, S. Nair, and M. Koyakuty, Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/ampli.ed refractory chronic myeloid leukemia. Mol. Pharm. 9, 3062 (2012).
23. P. Prabhu and V. Patravale, The upcoming field of theranostic nanomedicine: An overview. J. Biomed. Nanotechnol. 8, 859 (2012).
24. G. Bozzuto, P. Ruggieri, and A. Molinari, Molecular aspects of tumor cell migration and invasion. Ann. Ist. Super Sanita 46, 66 (2010).
25. C. L. Peng, P. S. Lai, F. H. Lin, Wu. S. Yueh-Hsiu, and M. J. Shieh, Dual chemotherapy and photodynamic therapy in an HT-29 human colon cancer xenograft model using SN-38-loaded chlorin-core star block copolymer micelles. Biomaterials 30, 3614 (2009).
26. A. Khdair, H. Handa, G. Mao, and J. Panyam, Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro. Eur. J. Pharm. Biopharm. 71, 214 (2009).
27. A. Khdair, D. Chen, Y. Patil, L. Ma, Q. P. Dou, M. P. Shekhar, and J. Panyam, Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. J. Control. Release 141, 137 (2010).
28. M. Kästle, S. Grimm, R. Nagel, N. Breusing, and T. Grune, Combination of PDT and inhibitor treatment affects melanoma cells and spares keratinocytes. Free Radic. Biol. Med. 50, 305 (2011).
29. S. H. Hu, S. Y. Chen, and X. Gao, Multifunctional nanocapsules for simultaneous encapsulation of hydrophilic and hydrophobic compounds and on-demand release. ACS Nano 6, 2558 (2012).
30. K. Löw, T. Knobloch, S. Wagner, A. Wiehe, A. Engel, K. Langer, and H. von Briesen, Comparison of intracellular accumulation and cytotoxicity of free mTHPC and mTHPC-loaded PLGA nanoparticles in human colon carcinoma cells. Nanotechnology 22, 245102 (2011).
31. M. Rojnik, P. Kocbek, F. Moret, C. Compagnin, L. Celotti, M. J. Bovis, J. H. Woodhams, A. J. Macrobert, D. Scheglmann, and W. Helfrich, In vitro and in vivo characterization of temopor.nloaded PEGylated PLGA nanoparticles for use in photodynamic therapy. Nanomedicine 7, 663 (2012).
32. P. Westerman, T. Glanzmann, S. Andrejevic, D. R. Braichotte, M. Forrer, G. A. Wagnieres, P. Monnier, H. van den Bergh, J. P. Mach, and S. Folli, Long circulating half-life and high tumor selectivity of the photosensitizer meta-tetrahydroxyphenylchlorin conjugated to polyethylene glycol in nude mice grafted with a human colon carcinoma. Int. J. Cancer. 76, 842 (1998).
33. P. F. C. Menezes, C. A. S. Melo, V. S. Bagnato, H. Imasato, and J. R. Perussi, Dark cytotoxicity of the photoproducts of the photosensitizer photogem after photobleaching induced by a laser. Laser Physics 15, 435 (2005).
34. A. P. Castano, T. N. Demidova, and M. R. Hamblin, Mechanisms in photodynamic therapy: Part one-photosensitizers, photochemistry and cellular localization. Photodiagnosis Photodyn. Ther. 1, 279 (2004).
35. L. Wang, X. Shi, C. Yang, and D. Huang, Versatile RBC-derived vesicles as nanoparticle vector of photosensitizers for photodynamic therapy. Nanoscale 5, 416 (2013).
36. S. J. Parsons and J. T. Parsons, Src family kinases, key regulators of signal transduction. Oncogene 23, 7906 (2004).
37. A. Angers-Loustau, R. Hering, T. E. Werbowetski, D. R. Kaplan, and R. F. Del Maestro, Src regulates actin dynamics and invasion of malignant glial cells in three dimensions. Mol. Cancer Res. 2, 595 (2004).
38. R. A. Dumont, I. Hildebrandt, H. Su, R. Haubner, G. Reischl, J. G. Czernin, P. S. Mischel, and W. A.Weber, Noninvasive imaging of αVβ3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. Cancer Res. 69, 3173 (2009).
39. V. Milano,Y. Piao, T. LaFortune, and J. De Groot, Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. Mol. Cancer Ther. 8, 394 (2009).
40. S. Ito, D. K. Werth, N. D. Richert, and I. Pastan, Vinculin phosphorylation by the src kinase. J. Biol. Chem. 258, 14626 (1983).
41. G. M. D'Abaco and A. H. Kaye, Integrins: Molecular determinants of glioma invasion. J. Clin. Neurosci. 14, 1041 (2007).
42. A. H. Lin, B. P. Eliceiri, and E. G. Levin, FAK mediates the inhibition of glioma cell migration by truncated 24 kDa FGF-2. Biochem. Biophys. Res. Commun. 382, 503 (2009).
43. 2:Gd3+ nano-contrast agent with enhanced longitudinal relaxivity for targeted cancer imaging. Nanoscale 3, 4150 (2011).
44. P. Mroz, A.Yaroslavsky, G. B. Kharkwal, and M. R. Hamblin, Cell death pathways in photodynamic therapy of cancer. Cancers 3, 2516 (2011).
45. W. N. Leung, X. Sun, N. K. Mak, and C. M. N. Yow, Photodynamic effects of mTHPC on human colon adenocarcinoma cells: photocytotoxicity, subcellular localization and apoptosis. Photochem. Photobiol. 75, 406 (2002).
46. N. L. Oleinick, R. L. Morris, and I. Belichenko, The role of apoptosis in response to photodynamic therapy: What, where, why, and how. Photochem. Photobiol. Sci. 1, 1 (2002).
47. D. Kessel and Y. Luo, Mitochondrial photodamage and PDT-induced apoptosis. J. Photochem. Photobiol. B 42, 89 (1998).
48. Y. Luo and D. Kessel, Initiation of apoptosis versus necrosis by photodynamic therapy with chloroaluminum phthalocyanine. Photochem. Photobiol. 66, 479 (1997).
49. R. Wahab, S. Dwivedi, A. Umar, S. Singh, I. H. Hwang, H. S. Shin, J. Musarrat, A. A. Al-Khedhairy, and Y. S. Kim, ZnO nanoparticles induce oxidative stress in Cloudman S91 melanoma cancer cells. J. Biomed. Nanotechnol. 9, 441 (2013).